Bluejay Diagnostics, Inc. (NASDAQ:BJDX – Get Free Report) saw a significant decrease in short interest in July. As of July 31st, there was short interest totalling 26,600 shares, a decrease of 29.4% from the July 15th total of 37,700 shares. Based on an average trading volume of 1,260,000 shares, the short-interest ratio is presently 0.0 days. Currently, 5.5% of the company’s stock are sold short.
Institutional Investors Weigh In On Bluejay Diagnostics
An institutional investor recently bought a new position in Bluejay Diagnostics stock. Armistice Capital LLC acquired a new position in shares of Bluejay Diagnostics, Inc. (NASDAQ:BJDX – Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 24,230 shares of the company’s stock, valued at approximately $30,000. Armistice Capital LLC owned approximately 1.95% of Bluejay Diagnostics as of its most recent SEC filing. Hedge funds and other institutional investors own 18.47% of the company’s stock.
Bluejay Diagnostics Trading Down 12.4 %
Shares of BJDX stock traded down $0.04 during trading hours on Friday, hitting $0.27. 1,247,481 shares of the company were exchanged, compared to its average volume of 541,224. The business has a 50 day moving average of $1.24 and a two-hundred day moving average of $3.99. Bluejay Diagnostics has a 52 week low of $0.25 and a 52 week high of $65.60. The company has a market capitalization of $90,048.00, a PE ratio of 0.00 and a beta of 0.81.
About Bluejay Diagnostics
Bluejay Diagnostics, Inc, a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components.
Featured Stories
- Five stocks we like better than Bluejay Diagnostics
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- How to Calculate Options Profits
- MarketBeat Week in Review – 8/12 – 8/16
- What is the Euro STOXX 50 Index?
- JD.com Earnings Surprise: China’s Outlook Better Than Expected
Receive News & Ratings for Bluejay Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluejay Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
